Mark joined Index in 2005 and works as Partner in the Life Science investment team. Now based in Jersey, his investments include Comentis, Molecular Partners, PanGenetics (acquired by Abbott), ProFibrix (acquired by The Medicines Company) and Versartis. He is also an advisor to the Utrecht University Technology Transfer Office and Holdings. Mark graduated in Biochemistry and has a PhD from the University of Amsterdam. He has worked for, managed and founded a number of early-stage biopharmaceutical companies in the field of innovative novel biopharmaceuticals.